FAM172A生物治疗肝癌的作用机制研究

摘要

目的 探讨FAM172A生物治疗肝癌的效果与相关作用机制.方法 选择在我院接受治疗的120例肝癌患者,随机分为观察组与对照组,各60例.对照组给予选择性肝动脉化疗栓塞(TACE)治疗,观察组在对照组治疗的基础上在术后给予FAM172A生物治疗.结果 观察组与对照组术后3个月的总有效率分别为76. 7％和46. 7％,观察组优于对照组(P<0. 05).观察组与对照组术后3个月的白细胞与血小板含量都明显高于术前(P<0. 05),组间对比差异无统计学意义(P>0. 05).观察组与对照组术后3个月的外周血CD3+细胞含量明显高于术前(P<0. 05),观察组术后3个月的外周血CD3+细胞含量也高于对照组(P<0. 05).观察组半年与1年存活率分别为91. 7％和66. 7％,对照组分别为73. 3％和51. 7％,观察组均高于对照组(P<0. 05).结论 FAM172A生物治疗肝癌提高患者的治疗效果与存活率,作用机制可能与改善患者的免疫功能、促进白细胞与血小板含量恢复正常等有关.%Objective To investigate the effects and related mechanism of FAM172A biological therapy for liver cancer. Methods From February 2013 to May 2016, 120 patients with liver cancer were treated in our hospital were selected as the research objects. All the patients were divided into observation group and control group with 60 patients in each group accorded to the principle of random envelope drawing, the control group was treated with TACE, and the observation group was received FAM172 A biological treatment on the basis of the treatment of the control group. Results The total effective rate of the observation group and the control group at 3 months after operation were 76. 7％ and 46. 7％, respectively, and the observation group was better than that of the control group (P<0. 05). The postoperative 3 months WBC and PLT content in the observation group and the control group were significantly higher than that preoperative(P<0. 05), and there were no significant difference between the two groups(P>0. 05). The postoperative 3 months of peripheral blood CD3+ cells observation group and the control group after 3 months of peripheral blood CD3+ cells were 65. 33％ + 4. 23％ and 54. 38％ + 11. 91％, significantly higher than the preoperative 45. 55％ + 12. 80％ and 45. 98％ + 13. 90％(P<0. 05),the content of CD3+ cells was observed 3 months postoperative peripheral blood group is higher than that of the control group(P<0. 05). The half year and 1 year survival rates of the observation group and the control group were 91. 7％ and 66. 7％, respectively, and 73. 3％ and 51. 7％ respectively in the control group, and the observation group was higher than that of the control group(P<0. 05). Conclusion FAM172A biological treatment of liver cancer can improve the treatment effect and survival rate, and the mechanism may be related to improving the immune function of patients and promoting the normal recovery of Ieukocytes and platelets.